TG Therapeutics TGTX (Seite 2)
eröffnet am 13.07.20 10:32:08 von
neuester Beitrag 06.05.24 23:08:41 von
neuester Beitrag 06.05.24 23:08:41 von
Beiträge: 470
ID: 1.327.694
ID: 1.327.694
Aufrufe heute: 3
Gesamt: 38.092
Gesamt: 38.092
Aktive User: 0
ISIN: US88322Q1085 · WKN: A1JXW7 · Symbol: NKB2
16,548
EUR
+1,14 %
+0,186 EUR
Letzter Kurs 09:31:38 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
01.05.24 · globenewswire  |
30.04.24 · globenewswire |
18.04.24 · globenewswire |
18.04.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,0000 | +99.999,00 | |
| 2,0600 | +24,85 | |
| 451,20 | +20,00 | |
| 8,7400 | +19,73 | |
| 3,1800 | +16,06 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,0400 | -10,02 | |
| 3,5200 | -12,87 | |
| 4,8500 | -14,31 | |
| 0,6460 | -19,25 | |
| 0,5801 | -19,43 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 75.080.370 von questionmark am 10.01.24 16:50:02Übertrieben , wird sich wieder erholen
kommt nicht so gut an, mal sehen, wo das heute endet
https://ir.tgtherapeutics.com/news-releases/news-release-det…
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
Jan 10, 2024
Preliminary U.S. BRIUMVI fourth quarter and full year 2023 net product revenue of approximately $40 million and $89 million, respectively
Preliminary year-end 2023 cash position of approximately $215 million
NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) yesterday announced preliminary U.S. net product revenue for BRIUMVI® for the fourth quarter and full year ended December 31, 2023 (unaudited), as well as financial guidance and development milestones for 2024, during a preannounced presentation at the 42nd Annual J.P Morgan Healthcare Conference. An audio replay of the event, as well as the corresponding slide deck are available on the Investors and Media section of the TG corporate website at ir.tgtherapeutics.com/events.
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are excited to share our preliminary fourth quarter and year end U.S. BRIUMVI net product revenue. As we head into 2024, we have our sights set on achieving revenue and expense targets and have built an ambitious plan to potentially expand the utility of BRIUMVI into new indications and for use as a subcutaneous injection. We are also excited to expand our R&D program with the recent licensing of azer-cel, an allogeneic CD19 CAR T therapy which we believe has the potential to become a meaningful therapy to treat various autoimmune disorders.”
Preliminary Fourth Quarter and Full Year 2023 Updates (based on unaudited financial information)
BRIUMVI U.S. net product revenue expected to be approximately $40 million and $89 million for the fourth quarter and full year of 2023, respectively
Year-end 2023 cash position of approximately $215 million
Preliminary selected financial information presented in this release are unaudited, subject to financial closing procedures and adjustment, and provided as an approximation in advance of the Company’s announcement of complete financial results planned to occur February 2024.
2024 Target Guidance
BRIUMVI U.S. net product revenue targets of approximately $41-$46 million and $220-$260 million for the first quarter and full year 2024, respectively
Full year 2024 target operating expense of approximately $250 million
2024 Development Pipeline Anticipated Milestones
Commence clinical development of subcutaneous BRIUMVI
Commence a trial evaluating BRIUMVI in additional autoimmune diseases outside of Multiple Sclerosis (MS)
Commence a trial evaluating azer-cel in autoimmune disease
Present data from the ENHANCE Phase 3b CD20 switch trial at multiple conferences throughout the year
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
Jan 10, 2024
Preliminary U.S. BRIUMVI fourth quarter and full year 2023 net product revenue of approximately $40 million and $89 million, respectively
Preliminary year-end 2023 cash position of approximately $215 million
NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) yesterday announced preliminary U.S. net product revenue for BRIUMVI® for the fourth quarter and full year ended December 31, 2023 (unaudited), as well as financial guidance and development milestones for 2024, during a preannounced presentation at the 42nd Annual J.P Morgan Healthcare Conference. An audio replay of the event, as well as the corresponding slide deck are available on the Investors and Media section of the TG corporate website at ir.tgtherapeutics.com/events.
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are excited to share our preliminary fourth quarter and year end U.S. BRIUMVI net product revenue. As we head into 2024, we have our sights set on achieving revenue and expense targets and have built an ambitious plan to potentially expand the utility of BRIUMVI into new indications and for use as a subcutaneous injection. We are also excited to expand our R&D program with the recent licensing of azer-cel, an allogeneic CD19 CAR T therapy which we believe has the potential to become a meaningful therapy to treat various autoimmune disorders.”
Preliminary Fourth Quarter and Full Year 2023 Updates (based on unaudited financial information)
BRIUMVI U.S. net product revenue expected to be approximately $40 million and $89 million for the fourth quarter and full year of 2023, respectively
Year-end 2023 cash position of approximately $215 million
Preliminary selected financial information presented in this release are unaudited, subject to financial closing procedures and adjustment, and provided as an approximation in advance of the Company’s announcement of complete financial results planned to occur February 2024.
2024 Target Guidance
BRIUMVI U.S. net product revenue targets of approximately $41-$46 million and $220-$260 million for the first quarter and full year 2024, respectively
Full year 2024 target operating expense of approximately $250 million
2024 Development Pipeline Anticipated Milestones
Commence clinical development of subcutaneous BRIUMVI
Commence a trial evaluating BRIUMVI in additional autoimmune diseases outside of Multiple Sclerosis (MS)
Commence a trial evaluating azer-cel in autoimmune disease
Present data from the ENHANCE Phase 3b CD20 switch trial at multiple conferences throughout the year
entwickelt sich prächtig, ohne relevante news, oder hab ich etwas verpasst?
Trading Spotlight
na, dann bleib ich doch erst mal dabei, 100 k stücke hat er sich gegönnt
Ich hab wieder verkauft. Erst möchte ich Verkaufserfolge sehen, bevor ich hier wieder ernsthaft investiere.
So, zweite tranche gekauft
Durchsuchen
